Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis | Zhang | Endokrynologia Polska
Source : https://journals.viamedica.pl/endokrynologia_polska/article/view/84675
Early publication date: 2022-02-14 Qiongfang Zhang 1, Lianxiang Deng 1, Cong Chen 1, Xu Pan 1, Shan Jiang 1 DOI: 10.5603/EP.a2021.0109 Endokrynol Pol 2022;73(1):110-120. The Second People's Hospital of Nanning,...
Conclusions: Overall, PSCK9 mAbs are an effective and safe method of LDL-C reduction in patients with FH.
Share
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-01013-x
Purpose of Review Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also...
Summary: Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.
Share
Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35367164/
1 Specialty Pharmacy Services, Vanderbilt University Medical Center, 726 Melrose Avenue Nashville, TN 37211, United States. Electronic address: [email protected]. 2 Specialty Pharmacy Services, Vanderbilt University Medical Center, 726 Melrose Avenue...
Conclusions: High rates of persistence to PCSK9i were seen in patients receiving care within an integrated specialty pharmacy model compared with rates in previous studies, suggesting specialty pharmacists may play a role in mitigating many common reasons for PCSK9i non-persistence.
Share
Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35386132/
2021 Nov 29;4(3):347-349. doi: 10.1016/j.cjco.2021.11.009. 1 Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 2 Robarts Research Institute, Schulich School of Medicine and Dentistry,...
Conclusion/Relevance: We describe an Ontario patient with HoFH who for 17 months has been treated with monthly infusions of evinacumab added to pre-existing statin, ezetimibe, and evolocumab therapy. Evinacumab in this HoFH patient was associated with markedly improved LDL-C levels and decreased frequency of apheresis.
Share
Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach - The Pharmacogenomics Journal
Source : https://www.nature.com/articles/s41397-022-00274-8
The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering drugs, frequently statins. Although pharmacogenomic clinical practice guidelines focusing on genotype-based statin...
Conclusion: This implementation approach facilitates the incorporation of pharmacogenomic studies in clinical care practice, it does not add complexity nor additional steps to laboratory processes, and improves the pharmacotherapeutic process of patients.
Share